Endpoints News 生物医药· Ryan Cross·· 3 天前AI 评分21
Marrow 获 1.73 亿美元融资,推进 siRNA 药物治疗镰状细胞病以竞批 CRISPR 疗法
Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell
AI 导读
基因疗法公司 Marrow 宣布获得 1.73 亿美元融资,用于开发 siRNA 药物,该药物将在镰状细胞病领域与 CRISPR 疗法竞争。此前 FDA 于 2023 年 12 月批准了两种镰状细胞病基因疗法,引发多家药企关注这一赛道。
正文
When the FDA approved two gene therapies for sickle cell disease in December 2023, many drugmakers viewed it as the end of the story and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news